SCHEMBL112672

SCHEMBL112672

CCOC(=O)c1cc(OCc2ccccc2)cc(C(=O)OCC)n1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.59
KMT2A Q03164 2/20 0.59
HSP90AA1 P07900 1/20 0.59
GABRA1 P14867 1/20 0.58
GABRG2 P18507 1/20 0.58
GABRB3 P28472 1/20 0.58
GABRA5 P31644 1/20 0.58
GABRA3 P34903 1/20 0.58
GABRA2 P47869 1/20 0.58
MAPT P10636 2/20 0.56
LMNA P02545 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
CYP1A2 P05177 1/20 0.55
MAOB P27338 1/20 0.54
PPARG P37231 1/20 0.51
MMP13 P45452 3/20 0.51
NMT1 P30419 2/20 0.50
ALDH1A1 P00352 2/20 0.50
NR1H4 Q96RI1 1/20 0.50
NMT2 O60551 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15892266 0.95 MEN1 (0.55) MEN1KMT2AHSP90AA1GABRA1GABRG2
SCHEMBL111721 0.90 MEN1 (0.53) MEN1KMT2AHSP90AA1GABRA1GABRG2
SCHEMBL3534571 0.85 LMNA (0.55) MEN1KMT2ALMNAMAOBALDH1A1
SCHEMBL4400182 0.82 KMT2A (0.67) MEN1KMT2AHSP90AA1GABRA1GABRG2
SCHEMBL5035686 0.82 MAOB (0.59) MEN1KMT2ALMNAL3MBTL1CYP1A2
SCHEMBL226698 0.82 P4HTM (0.69) MEN1KMT2AHSP90AA1GABRA1GABRG2
SCHEMBL3532550 0.82 LMNA (0.55) MEN1KMT2ALMNAMAOBALDH1A1
SCHEMBL14278777 0.82 MEN1 (0.65) MEN1KMT2ALMNACYP1A2MAOB
SCHEMBL5004775 0.81 CYP1A2 (0.60) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL20944487 0.81 MEN1 (0.60) MEN1KMT2AHSP90AA1GABRA1GABRG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8969549-B2 Antioxidant small molecules aimed at targeting metal-based oxidative stress in neurogenerative disorders TEXAS CHRISTIAN UNIVERSITY (US) 2015-03-03 US disclosed
US-8969549-B2 Antioxidant small molecules aimed at targeting metal-based oxidative stress in neurogenerative disorders TEXAS CHRISTIAN UNIVERSITY (US) 2015-03-03 US disclosed
US-20140206862-A1 Antioxidant Small Molecules Aimed at Targeting Metal-Based Oxidative Stress in Neurogenerative Disorders TEXAS CHRISTIAN UNIVERSITY (US) 2014-07-24 US disclosed
WO-2014113624-A1 ANTIOXIDANT SMALL MOLECULES AIMED AT TARGETING METAL-BASED OXIDATIVE STRESS IN NEURODEGNERATIVE DISORDERS TEXAS CHRISTIAN UNIVERSITY (US) 2014-07-24 WO disclosed
US-20140206862-A1 Antioxidant Small Molecules Aimed at Targeting Metal-Based Oxidative Stress in Neurogenerative Disorders TEXAS CHRISTIAN UNIVERSITY (US) 2014-07-24 US disclosed
EP-2424860-A1 HETEROARYLTHIOMETHYL PYRIDINE DERIVATIVE MSD K.K. (JP) 2012-03-07 EP disclosed
US-20120028970-A1 HETEROARYLTHIOMETHYL PYRIDINE DERIVATIVE MSD K.K. (JP) 2012-02-02 US disclosed
US-20110015181-A1 ALKYLAMINOPYRIDINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2011-01-20 US disclosed
EP-2264026-A1 ALKYLAMINOPYRIDINE DERIVATIVE Banyu Pharmaceutical Co., Ltd. (JP) 2010-12-22 EP disclosed
WO-2010126163-A1 HETEROARYLTHIOMETHYL PYRIDINE DERIVATIVE BANYU PHARMACEUTICAL CO.,LTD. (JP) 2010-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120028970-A1 HETEROARYLTHIOMETHYL PYRIDINE DERIVATIVE AR, NR5A1, ARL1 MEN1 681/4885KMT2A 1493/4885HSP90AA1 1772/4885
US-20140206862-A1 Antioxidant Small Molecules Aimed at Targeting Metal-Based Oxidative Stress in Neurogenerative Disorders PYCR1, PRNP, NLN MEN1 890/4885KMT2A 3463/4885HSP90AA1 2581/4885
US-20110015181-A1 ALKYLAMINOPYRIDINE DERIVATIVE NPY4R, NPY1R, NPY2R MEN1 1674/4885KMT2A 3144/4885HSP90AA1 3494/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.